근위축측삭경화증에 대한 치료약물 임상시험 현황
Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by progressive death of motor neurons in the cortex, brainstem, and spinal cord. Until now, many treatment strategies have been tested in ALS, but so far only Riluzole has shown efficacy of slightly slowing disease progression. The pathophysiological mechanisms underlying ALS are multifactorial, with a complex interaction between genetic factors and molecular pathways. Other motor neuron disease such as spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA) are also progressive neurodegenerative disease with loss of motor neuron as ALS. This common thread of motor neuron loss has provided a target for the development of therapies for these motor neuron diseases. A better understanding of these pathogenic mechanisms and the potential pathological relationship between the various cellular processes have suggested novel therapeutic approaches, including stem cell and genetics-based strategies, providing hope for feasible treatment of ALS. (Korean J Clin Neurophysiol 2015;17:1-16)
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by progressive death of motor neurons in the cortex, brainstem, and spinal cord. Until now, many treatment strategies have been tested in ALS, but so far only Riluzole has shown efficacy of slightly slowing disease progression. The pathophysiological mechanisms underlying ALS are multifactorial, with a complex interaction between genetic factors and molecular pathways. Other motor neuron disease such as spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA) are also progressive neurodegenerative disease with loss of motor neuron as ALS. This common thread of motor neuron loss has provided a target for the development of therapies for these motor neuron diseases. A better understanding of these pathogenic mechanisms and the potential pathological relationship between the various cellular processes have suggested novel therapeutic approaches, including stem cell and genetics-based strategies, providing hope for feasible treatment of ALS. (Korean J Clin Neurophysiol 2015;17:1-16)
참고문헌 (52)
- Morren JA, "Current and prospective diseasemodifying therapies for amyotrophic lateral sclerosis", Expert Opin Investig Drugs, 21, pp.297~320 (2012)
- Bensimon G, "A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS", Riluzole Study Group, 1994, pp.330, 585~591
- Miller RG, "Riluzole for amyotrophic lateral sclerosis (ALS)", motor neuron disease (MND), 2012, pp.3, CD001447~
- Miller RG, "Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis", Neurology, 56, pp.843~848 (2001)
- Cudkowicz ME, "Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis", Neurology, 61, pp.456~464 (2003)
- Ryberg H, "A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine:effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters", Acta Neurol Scand, 108, pp.1~8 (2003)
- Piepers S, "Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis", Ann Neurol, 66, pp.227~234 (2009)
- "Amyotrophic lateral sclerosis" (2015)[URL]
- Tateishi N, "Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits", J Cereb Blood Flow Metab, 22, pp.723~734 (2002)
- de Carvalho M, "A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis", Amyotroph Lateral Scler, 11, pp.456~460 (2010)
- Goyal NA, "Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs", Expert Opin Investig Drugs, 23, pp.1541~1551 (2014)
- Pascuzzi RM, "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis", Amyotroph Lateral Scler, 11, pp.266~271 (2010)
- Berry JD, "Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis", PLoS One, 8, pp.e61177~ (2013)
- Kong Q, "Small-molecule activator of glutamate transporter EAAT2translation provides neuroprotection", J Clin Invest, 124, pp.1255~1267 (2014)
- Izumi Y, "Clinical trials of ultra-high-dose methylcobalamin in ALS", Brain Nerve, 59, pp.1141~1147 (2007)
- Desnuelle C, "A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis", Amyotroph Lateral Scler Other Motor Neuron Disord, 2, pp.9~18 (2001), ALS riluzole-tocopherol Study Group
- Orrell RW., "AEOL-10150 (Aeolus)", Curr Opin Investig Drugs, 7, pp.70~80 (2006)
- Abe K, "Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients", Amyotroph Lateral Scler Frontotemporal Degener, 15, pp.610~617 (2014)
- Yoshino H, "Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)", Amyotroph Lateral Scler, 7, pp.241~245 (2006)
- "ALSTDI homepage. Research center: Clinical Trials" (2015)[URL]
- Louwerse ES, "Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis", Arch Neurol, 52, pp.559~564 (1995)
- Paganoni S, "Uric acid levels predict survival in men with amyotrophic lateral sclerosis", J Neurol, 259, pp.1923~1928 (2012)
- Zinman L, "Emerging targets and treatments in amyotrophic lateral sclerosis", Lancet Neurol, 10, pp.481~490 (2011)
- Gordon PH, "Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial", Lancet Neurol, 6, pp.1045~1053 (2007)
- Shefner JM, "A clinical trial of creatine in ALS", Neurology, 63, pp.1656~1661 (2004)
- Kaufmann P, "Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III", Ann Neurol, 66, pp.235~244 (2009)
- Cudkowicz M, "The effects of dexpramipexole (KNS-760704)in individuals with amyotrophic lateral sclerosis", Nat Med, 17, pp.1652~1656 (2011)
- Cudkowicz ME, "Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial", Lancet Neurol, 12, pp.1059~1067 (2013)
- Lenglet T, "A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis", Eur J Neurol, 21, pp.529~536 (2014)
- 민주홍, "Oral Solubilized Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis: A Randomized Cross-Over Trial", Journal of Korean Medical Science, 27(2), pp.200~206 (2012), 대한의학회
- Weishaupt JH, "Reduced oxidative damage in ALS by highdose enteral melatonin treatment", J Pineal Res, 41, pp.313~323 (2006)
- Keep M, "Intrathecal cyclosporin prolongs survival of late-stage ALS mice", Brain Res, 894, pp.327~331 (2001)
- Cudkowicz ME, "Trial of celecoxib in amyotrophic lateral sclerosis", Ann Neurol, 60, pp.22~31 (2006)
- Stommel EW, "Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial", Amyotroph Lateral Scler, 10, pp.393~404 (2009)
- Meininger V, "Glatiramer acetate has no impact on disease progression in ALS at 40 mg", day: a double-blind, randomized, multicentre, placebo-controlled trial, 2009, pp.10, 378~383
- Miller RG, "NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study", Amyotroph Lateral Scler Frontotemporal Degener, 15, pp.601~609 (2014)
- Dupuis L, "A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis", PLoS One, 7, pp.e37885~ (2012)
- Sorenson EJ, "Subcutaneous IGF-1 is not beneficial in 2-year ALS trial", Neurology, 71, pp.1770~1775 (2008)
- Hansen R, "Tirasemtiv amplifies skeletal muscle response to nerve activation in humans", Muscle Nerve, 50, pp.925~931 (2014)
- Meininger V, "Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials", Amyotroph Lateral Scler Other Motor Neuron Disord, 5, pp.107~117 (2004)
- Scelsa SN, "A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS", Neurology, 64, pp.1298~1300 (2005)
- Miller R, "Phase II", III randomized trial of TCH346in patients with ALS, 2007, pp.69, 776~784
- Meininger V, "Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial", Neurology, 66, pp.88~92 (2006)
- Cross AH, "Established and novel disease-modifying treatments in multiple sclerosis", J Intern Med, 275, pp.350~363 (2014)
- Cudkowicz ME, "Phase 2 study of sodium phenylbutyrate in ALS", Amyotroph Lateral Scler, 10, pp.99~106 (2009)
- Kalmar B, "The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol", Pharmacol Ther, 141, pp.40~54 (2014)
- Cudkowicz ME, "Arimoclomol at dosages up to 300 mg", day is well tolerated and safe in amyotrophic lateral sclerosis, 2008, pp.38, 837~844
- Aggarwal SP, "Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial", Lancet Neurol, 9, pp.481~488 (2010)
- Dunlop RA, "The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation", PLoS One, 8, pp.e75376~ (2013)
- Miller TM, "An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study", Lancet Neurol, 12, pp.435~442 (2013)
- Shefner J, "Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis", Amyotroph Lateral Scler, 13, pp.430~438 (2012)
- Thomsen GM, "The past, present, and future of stem cell clinical trials for ALS", Exp Neurol, 262, pp.127~137 (2014)